The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s liposomal drug delivery devices market report forecasts the liposomal drug delivery devices market size to grow to 6.72 Billion by 2027, with a CAGR (compound annual growth rate) of more than 10%.

Learn More On The Liposomal Drug Delivery Devices Market Report 2023 – https://www.thebusinessresearchcompany.com/report/liposomal-drug-delivery-devices-global-market-report

Liposomal Drug Delivery Devices Market Size Forecast
The global liposomal drug delivery devices market is expected to grow from $4.1 billion in 2022 to $4.5 billion in 2023 at a compound annual growth rate (CAGR) of 9.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The liposomal drug delivery devices market is expected to grow from $6.72 billion in 2027 at a CAGR of 10.6%.

North America held the largest liposomal drug delivery devices market share.

Key Liposomal Drug Delivery Devices Market Driver ­– Rise In The Number Of Cancer Cases Globally
According to the American Cancer Society, there were 1.9million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the liposomal drug delivery devices market over the forthcoming years.

Request for A Sample Of The Global Liposomal Drug Delivery Devices Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3349&type=smp

Key Liposomal Drug Delivery Devices Market Trend – Undertaking Various Strategic Initiatives
Several big companies are undertaking various strategic initiatives such as collaborations and new product development, which is likely to become a major trend in the liposomal drug delivery devices market. Various companies are coming together to develop liposomal drug delivery systems to expand their product portfolio and operations worldwide. For instance, in 2021, MindMed is an Israeli creative drug development company, announced the execution of a Memorandum of Understanding regarding the introduction of an exclusive collaborative development program to optimize the supply of particular psychedelic drug candidates, leveraging Nextage’s proprietary Brain Targeting Liposome System (BTLS) supply technology, for which it has a license. In March 2020, FUJIFILM Corporation announced its decision to offer contract services of process development and manufacturing of liposome formulations to its partners seeking drug delivery formulations that are designed to deliver the therapeutic to the affected sites.

Liposomal Drug Delivery Devices Market Segment
1) By Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types
2) By Application: Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy
3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Other End Users

Liposomal Drug Delivery Devices Market Major Players and Strategies
Major players in the liposomal drug delivery devices market are Fudan-Zhangjiang, Pacira, Johnson and Johnson, Gilead Sciences, Novartis, Luye Pharma, CSPC, Ipsen (Onivyde), Teva Pharmaceutical, and Sigma-Tau Group.

In July 2020, Croda International, PLC., a UK-based specialty chemicals company, acquired Avanti Polar Lipids, Inc. for $260 million. The acquisition is expected to expand life sciences products, cGMP production capabilities, and pharmaceutical services for biotechnology, life science, and expand customers for Croda International. Avanti Polar Lipids Inc. is a USA-based company that specializes in lipid-based drug delivery technology for next-generation pharmaceuticals.

The Liposomal Drug Delivery Devices Global Market Report 2023 covers regional data on liposomal drug delivery devices market size, liposomal drug delivery devices market trends and drivers, opportunities, strategies, and liposomal drug delivery devices market competitor analysis. The countries covered in the liposomal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Liposomal drug delivery devices are microscopic colloidal spheres that are used to deliver drug molecules to the site of action.

View More Reports Related To The Liposomal Drug Delivery Devices Market –
Liposuction Surgery Devices Global Market Report 2023
Spinal Surgery Devices And Equipment Global Market Report 2023
Laser Technology Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: